Content deleted Content added
Citation bot (talk | contribs) Added date. Removed parameters. | Use this bot. Report bugs. | Suggested by GrapesRock | #UCB_toolbar |
GreenC bot (talk | contribs) Rescued 1 archive link. Wayback Medic 2.5 per WP:URLREQ#xyz.reuters.com |
||
Line 14:
The group operates in all three segments of nuclear medicine ([[Positron emission tomography|PET]], [[SPECT]] and [[radionuclide therapy|therapy]]) to diagnose and treat serious conditions in the fields of [[oncology]], [[neurology]], [[cardiology]], infectious and inflammatory [[diseases]].<ref name="AAA2">[http://www.ilsole24ore.com/art/impresa-e-territori/2014-03-12/dal-cern-biopark-canavese-064227.shtml?uuid=ABvohR2&fromSearch Il Sole 24 Ore, "Dal Cern and Biopark canavese", March 12th, 2014]</ref>
In late October 2017, ''[[Reuters]]'' announced that [[Novartis]] would acquire the company for $3.9 billion, paying $41 per ordinary share and $82 per American depositary share representing a 47 percent premium.<ref>{{Cite news|url=http://uk.reuters.com/article/uk-novartis-advanced-accelerator/novartis-to-buy-frances-advanced-accelerator-for-3-9-billion-idUKKBN1CZ0KM|archive-url=https://web.archive.org/web/20201205154247/https://uk.reuters.com/article/uk-novartis-advanced-accelerator/novartis-to-buy-frances-advanced-accelerator-for-3-9-billion-idUKKBN1CZ0KM|url-status=dead|archive-date=December 5, 2020|title = Novartis to buy French cancer specialist AAA for $3.9 billion|newspaper = Reuters|date = 3 November 2017|last1 = Miller|first1 = John}}</ref> On January 22, 2018, Novartis AG announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A.<ref>{{Cite press release |title=Novartis Completes Tender Offer for Advanced Accelerator Applications |date=23 January 2018 |publisher=Novartis |url=https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-advanced-accelerator-applications-sa-and-announces-commencement-subsequent-offering-period}}</ref>
==History==
| |||